PTI Proteostasis Therapeutics Inc.

1.91
-0.05  -3%
Previous Close 1.96
Open 2
Price To Book 1.39
Market Cap 97,656,344
Shares 51,128,976
Volume 1,890,833
Short Ratio
Av. Daily Volume 6,434,998
Stock charts supplied by TradingView

NewsSee all news

  1. Proteostasis Therapeutics Regulatory Update Following Scientific Advice Meeting with MHRA

    BOSTON, Jan. 13, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  2. Proteostasis Therapeutics Announces Positive Phase 2 Topline Results from Proprietary CFTR Modulator Combinations in F508del Homozygous Cystic Fibrosis Patients

    BOSTON, Dec. 17, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  3. Proteostasis Therapeutics to Initiate First Ever Personalized Medicine-Based Clinical Trial, CHOICES, in European CF Patients with Genotypes Ineligible for Approved CFTR Modulators

    BOSTON, Dec. 11, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  4. Proteostasis Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference

    BOSTON, Dec. 3, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  5. Proteostasis Therapeutics Regains Compliance with Nasdaq Listing Standards

    BOSTON, Dec. 2, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 28-day data released December 11, 2017 - showed improvements in FEV1 of 5.2%. Phase 2 28-day data released December 11, 2017 - showed improvements in FEV1 of 5.2%.
PTI-428
Cystic fibrosis
Development to be discontinued due to lack of efficacy - March 25, 2019.
PTI-801 + Symdeko
Cystic fibrosis
Proceed to 28 day studies to confirm efficacy.
PTI-801 and PTI-808
Cystic fibrosis
Phase 2 negative data released December 17, 2019. Mean changes in ppFEV1 were not statistically significant in the heterozygous population. Phase 3 trial to be initiated in 2020.
PTI-428 + PTI-801 + PTI-808
Cystic fibrosis
Development to be discontinued due to lack of efficacy.
PTI-428 + Symdeko
Cystic fibrosis

Latest News

  1. Proteostasis Therapeutics Regulatory Update Following Scientific Advice Meeting with MHRA

    BOSTON, Jan. 13, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  2. Proteostasis Therapeutics Announces Positive Phase 2 Topline Results from Proprietary CFTR Modulator Combinations in F508del Homozygous Cystic Fibrosis Patients

    BOSTON, Dec. 17, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  3. Proteostasis Therapeutics to Initiate First Ever Personalized Medicine-Based Clinical Trial, CHOICES, in European CF Patients with Genotypes Ineligible for Approved CFTR Modulators

    BOSTON, Dec. 11, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  4. Proteostasis Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference

    BOSTON, Dec. 3, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  5. Proteostasis Therapeutics Regains Compliance with Nasdaq Listing Standards

    BOSTON, Dec. 2, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  6. Proteostasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    BOSTON, Nov. 7, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  7. Proteostasis Therapeutics Announces Completion of Enrollment in Global Phase 2 Study in Cystic Fibrosis

    BOSTON, Nov. 6, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  8. Proteostasis Therapeutics Announces Presentations Highlighting its CFTR Modulators at the North American Cystic Fibrosis Conference

    BOSTON, Oct. 24, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  9. Proteostasis Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

    BOSTON, Sept. 26, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  10. Proteostasis Therapeutics Announces Presentation at the UK Cystic Fibrosis Conference

    BOSTON, Sept.19, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic